Hochschulschrift
Dendritic cell-based immunotherapy : implications for novel vaccines from hSIGN and HUT9 mice
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
München, Techn. Univ., Diss., 2009
- Urheber
- URN
-
urn:nbn:de:bvb:91-diss-20080908-672631-1-5
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Objekttyp
- Hochschulschrift
Beteiligte
Ähnliche Objekte (12)
Specific microtubule-depolymerizing agents augment efficacy of dendritic cell-based cancer vaccines
Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma
Immunotherapy and vaccines
Dendritic cell-based immunotherapy of hormone refractory prostate carcinoma (HRPCa) – a pilot trial
Cell-permeable transgelin-2 as a potent therapeutic for dendritic cell-based cancer immunotherapy
Route of antigen delivery impacts the immunostimulatory activity of dendritic cell-based vaccines for hepatocellular carcinoma
CD8+ T cell-based cancer immunotherapy
The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer
Current status of dendritic cell-based tumor vaccination
p16INK4a as target for T cell-based cancer immunotherapy
Editorial : Next generation γδ T cell-based tumor immunotherapy
Mechanism of dendritic cell-based vaccination against Leishmania major
Specific microtubule-depolymerizing agents augment efficacy of dendritic cell-based cancer vaccines
Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma
Immunotherapy and vaccines
Dendritic cell-based immunotherapy of hormone refractory prostate carcinoma (HRPCa) – a pilot trial
Cell-permeable transgelin-2 as a potent therapeutic for dendritic cell-based cancer immunotherapy
Route of antigen delivery impacts the immunostimulatory activity of dendritic cell-based vaccines for hepatocellular carcinoma
CD8+ T cell-based cancer immunotherapy
The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer
Current status of dendritic cell-based tumor vaccination
p16INK4a as target for T cell-based cancer immunotherapy
Editorial : Next generation γδ T cell-based tumor immunotherapy
Mechanism of dendritic cell-based vaccination against Leishmania major
Specific microtubule-depolymerizing agents augment efficacy of dendritic cell-based cancer vaccines
Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma
Immunotherapy and vaccines
Dendritic cell-based immunotherapy of hormone refractory prostate carcinoma (HRPCa) – a pilot trial
Cell-permeable transgelin-2 as a potent therapeutic for dendritic cell-based cancer immunotherapy
Route of antigen delivery impacts the immunostimulatory activity of dendritic cell-based vaccines for hepatocellular carcinoma
CD8+ T cell-based cancer immunotherapy
The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer
Current status of dendritic cell-based tumor vaccination
p16INK4a as target for T cell-based cancer immunotherapy
Editorial : Next generation γδ T cell-based tumor immunotherapy